Lisanti Capital Growth LLC Trims Stake in ARS Pharmaceuticals, Inc. $SPRY

Lisanti Capital Growth LLC lessened its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 49.7% in the third quarter, HoldingsChannel reports. The firm owned 211,189 shares of the company’s stock after selling 208,886 shares during the quarter. Lisanti Capital Growth LLC’s holdings in ARS Pharmaceuticals were worth $2,122,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SPRY. CWM LLC grew its stake in ARS Pharmaceuticals by 243.7% in the third quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after purchasing an additional 1,806 shares during the period. Osaic Holdings Inc. boosted its holdings in shares of ARS Pharmaceuticals by 52.8% during the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after buying an additional 1,803 shares in the last quarter. CX Institutional purchased a new stake in shares of ARS Pharmaceuticals in the 3rd quarter worth about $92,000. Ameritas Investment Partners Inc. grew its position in shares of ARS Pharmaceuticals by 16.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock worth $98,000 after buying an additional 777 shares during the period. Finally, RiverPark Advisors LLC bought a new position in shares of ARS Pharmaceuticals in the 2nd quarter worth about $100,000. 68.16% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, COO Brian Dorsey sold 21,828 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $8.71, for a total transaction of $190,121.88. Following the completion of the sale, the chief operating officer owned 10,789 shares of the company’s stock, valued at approximately $93,972.19. The trade was a 66.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Justin Chakma sold 166,380 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $8.87, for a total value of $1,475,790.60. Additional details regarding this sale are available in the official SEC disclosure. 33.50% of the stock is currently owned by insiders.

ARS Pharmaceuticals Price Performance

NASDAQ SPRY opened at $9.99 on Friday. ARS Pharmaceuticals, Inc. has a 1-year low of $6.66 and a 1-year high of $18.90. The business’s fifty day moving average price is $10.58 and its 200-day moving average price is $11.52. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51. The stock has a market capitalization of $987.51 million, a price-to-earnings ratio of -12.33 and a beta of 0.80.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The business had revenue of $32.50 million during the quarter, compared to the consensus estimate of $28.87 million. ARS Pharmaceuticals had a negative return on equity of 38.77% and a negative net margin of 56.06%. On average, equities analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Roth Mkm assumed coverage on shares of ARS Pharmaceuticals in a research note on Tuesday, November 4th. They set a “buy” rating and a $30.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a report on Wednesday, January 21st. Finally, Zacks Research downgraded ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Four equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $33.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.